Ethos Technologies: Short Interest Doubles, CEO Sells Ahead of Q3 Print

LIFE enters its November 3 earnings report with short interest that has nearly doubled over the past month and its CEO reducing his stake on a pre-arranged plan, a combination that makes the ownership picture the most telling data point ahead of today's release.

Among LIFE's closest peers on ORTEX, short interest positioning is relatively modest by sector standards. LIFE's own short position has risen sharply, roughly 86% over the past month to approximately 3.96 million shares, though without a free float figure the percentage cannot be quoted precisely. What is clear from the trajectory is that conviction among bears has grown quickly. The ORTEX short score has hovered in the 55 to 59 range over the past two weeks, a middling but watchward reading that suggests the short community is engaged but not yet at an extreme. Borrow conditions remain loose: availability runs at 418%, meaning roughly four shares are available to lend for every one already borrowed, and the cost to borrow has crept up only modestly to 1.22%, around 10% higher than a week ago. There is no squeeze pressure in the lending pool.

The insider picture tells a sharper story. CEO Peter Colis sold approximately $2.7 million in open-market shares on October 15 and 16, all under a pre-arranged 10b5-1 plan. President Lingke Wang also sold around $885,000 on the same dates, again under a plan. Planned sales are a weaker signal than discretionary ones, but the net 90-day insider position across the company is a disposal of roughly 455,000 shares worth $17.4 million. Both executives remain among the largest individual holders, Colis at just under 10% and Wang at just over 9%, so the sales trim rather than exit positions. Still, the direction is one-way.

Analyst opinion has drifted in two directions since the last print. JP Morgan downgraded to Neutral on October 1, holding its $37 target unchanged, a signal that the firm sees limited upside rather than fundamental deterioration. Citizens moved the other way on October 12, raising its target from $33 to $40 while keeping a Market Outperform rating. At $42.62, LIFE has already traded through both of those revised targets, leaving the consensus mean of $37.50 below the current price. The stock is up 25% over the past month, a move that has compressed the margin of safety that most bull cases assumed. The options market is not signalling concern: the put/call ratio is 0.019, close to the floor of its 52-week range, with calls heavily dominating. That lopsided call skew fits a stock that has run hard and where momentum traders rather than hedgers are most active.

ORTEX puts the probability of LIFE joining the MSCI World Small, MSCI USA IMI, MSCI USA Small and MSCI World IMI indices at 51% each, tied to the November 2026 quarterly review. If confirmed, the announcement would come on November 11 with passive buying due on November 30. At $2.8 billion market cap and 61% above the price line that governs eligibility, inclusion is already the base case. The combined passive flow across those indices would total roughly $124 million, equivalent to less than a day of normal trading volume. That is a tailwind, not a transformer, but it is a concrete mechanical buyer sitting just beyond today's print.

Today's report is therefore a test of whether the company's underlying economics, carrier commission stability and policy retention rates, can justify a stock that has already run well ahead of where most analysts were prepared to plant their flags.